2 results
Approved WMOPending
The primary objective is to determine the efficacy of the neuroprotectant, nerinetide in:• Reducing global disability in participants with acute ischemic stroke (AIS)
Approved WMORecruiting
Primary Objective: To evaluate the long-term safety (including progression to acute myeloid leukemia (AML) and/or other malignancies/pre-malignancies) of luspatercept in subjects who have participated in other luspatercept clinical trials.Secondary…